TTNP Stock Overview
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Titan Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.10 |
52 Week High | US$16.60 |
52 Week Low | US$5.00 |
Beta | 1.35 |
1 Month Change | -3.14% |
3 Month Change | 15.26% |
1 Year Change | -55.35% |
3 Year Change | -85.39% |
5 Year Change | -99.35% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?
Jul 10Titan Pharma regains Nasdaq listing compliance
Dec 16Titan Pharmaceuticals announces 1-for-30 reverse stock split
Nov 30Titan Pharmaceuticals EPS misses by $0.01, beats on revenue
Nov 16Titan Pharma closes debt settlement and JT-09 acquisition
Nov 02Titan Pharma to raise $8M in stock offering
Oct 28Shareholder Returns
TTNP | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -3.3% | -3.2% | -3.5% |
1Y | -55.3% | 11.7% | 20.2% |
Return vs Industry: TTNP underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: TTNP underperformed the US Market which returned 20.2% over the past year.
Price Volatility
TTNP volatility | |
---|---|
TTNP Average Weekly Movement | 15.0% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TTNP's share price has been volatile over the past 3 months.
Volatility Over Time: TTNP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 4 | David Lazar | www.titanpharm.com |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.
Titan Pharmaceuticals, Inc. Fundamentals Summary
TTNP fundamental statistics | |
---|---|
Market cap | US$6.63m |
Earnings (TTM) | -US$5.57m |
Revenue (TTM) | US$184.00k |
35.3x
P/S Ratio-1.2x
P/E RatioIs TTNP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TTNP income statement (TTM) | |
---|---|
Revenue | US$184.00k |
Cost of Revenue | US$1.91m |
Gross Profit | -US$1.73m |
Other Expenses | US$3.84m |
Earnings | -US$5.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -6.09 |
Gross Margin | -939.67% |
Net Profit Margin | -3,026.63% |
Debt/Equity Ratio | 7.5% |
How did TTNP perform over the long term?
See historical performance and comparison